Results 51 to 60 of about 11,407 (210)

German Multicenter Study Analyzing Antimicrobial Activity of Ceftazidime-Avibactam of Clinical Meropenem-Resistant Pseudomonas aeruginosa Isolates Using a Commercially Available Broth Microdilution Assay

Antibiotics, 2022
Multidrug resistance is an emerging healthcare issue, especially concerning Pseudomonas aeruginosa. In this multicenter study, P. aeruginosa isolates with resistance against meropenem detected by routine methods were collected and tested for ...
Jana Manzke, Raphael Stauf, Bernd Neumann, Ernst Molitor, Gunnar Hischebeth, Michaela Simon, Jonathan Jantsch, Jürgen Rödel, Sören L. Becker, Alexander Halfmann, Thomas A. Wichelhaus, Michael Hogardt, Annerose Serr, Christina Hess, Andreas F. Wendel, Ekkehard Siegel, Holger Rohde, Stefan Zimmermann, Jörg Steinmann   +18 more
doaj   +1 more source

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study [PDF]

, 2016
Background Carbapenems are frequently the last line of defence in serious infections due to multidrug-resistant Gram-negative bacteria, but their use is threatened by the growing prevalence of carbapenemase-producing pathogens.
Armstrong, J., Carmeli, Y., Gasink, L.B., Laud, P.J., Newell, P., Stone, G., Wardman, A.   +6 more
core   +1 more source

Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying bla_KPC-2 Reveals a Heterogenous Population and Reversible Genotype

mSphere, 2018
A blaKPC-2-carrying Citrobacter freundii isolate developed ceftazidime-avibactam resistance during treatment with this agent. The initial and follow-up isolates exhibited ceftazidime-avibactam MICs of 4 and 64 µg/ml, respectively. Overexpression of AcrAB-
Mariana Castanheira, S. J. Ryan Arends, Andrew P. Davis, Leah N. Woosley, Amira A. Bhalodi, Shawn H. MacVane   +5 more
doaj   +1 more source

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

Antibiotics, 2021
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
George L. Daikos, Clóvis Arns da Cunha, Gian Maria Rossolini, Gregory G. Stone, Nathalie Baillon-Plot, Margaret Tawadrous, Paurus Irani   +6 more
doaj   +1 more source

identifying allosteric networks to fight antibiotics resistance [PDF]

, 2018
The rise of multi-drug resistance in bacterial pathogens is one of the grand challenges facing medical science. A major concern is the speed of development of β-lactamase-mediated resistance in Gram-negative species, thus putting at risk the efficacy of ...
Afsharikho, Hamidreza, Barnes, Melissa D., Bonomo, Robert A., Galdadas, Ioannis, Gervasio, Francesco L., Haider, Shozeb, Healy, Jess, Lovera, Silvia, Pérez-Hernández, Guillermo, Woodford, Neil   +9 more
core   +1 more source

Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]

, 2020
We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak, Buetti, Niccolo, Casanova, Carlo, Furrer, Hansjakob, Jent, Philipp, Livermore, David M, Lo Priore, Elia, Pelzer, Niklas   +7 more
core   +2 more sources

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021

Journal of Global Antimicrobial Resistance, 2023
: Objectives: To report the in vitro susceptibility of Enterobacterales (n = 3905) and Pseudomonas aeruginosa (n = 1,109) isolates, collected from patients in sub-Saharan Africa (four countries) in 2017–2021, to a panel of 10 antimicrobial agents with a
Mark G. Wise, James A. Karlowsky, Meredith A. Hackel, Mohamed Amine Harti, Bontle M.E. Ntshole, Eva Njeri Njagua, Rita Oladele, Catherine Samuel, Shameema Khan, Jeannette Wadula, Warren Lowman, Busisani W. Lembede, Daniel F. Sahm   +12 more
doaj   +1 more source

Treatment of infections caused by multidrug-resistant Gram-negative bacteria:Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party [PDF]

, 2018
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and ...
Enoch, David A, Hawkey, Peter M, Livermore, David M, McNulty, Cliodna A M, Otter, Jonathan A, Warren, Roderic E, Wilson, A Peter R   +6 more
core   +1 more source

621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates [PDF]

Open Forum Infectious Diseases, 2019
Abstract Background Ceftazidime–avibactam (CAZ-AVI) is a new antibiotic with activity against many Carbapenem-resistant Enterobacteriaceae (CRE). Although CAZ-AVI resistance in CRE has been reported, it is not consistently assessed. Our study aimed to assess the prevalence of CAZ-AVI resistance in CRE
Belal, Maymonah, Villasis, Lori, Diago-Navarro, Elizabeth, Motley, Michael, Young; Eric Spitzer, Allen, Fries, Bettina C, Monteforte, Melinda   +6 more
openaire   +1 more source

Cephem Potentiation by Inactivation of Nonessential Genes Involved in Cell Wall Biogenesis of ß-Lactamase-Producing Escherichia coli [PDF]

, 2017
Reversal of antimicrobial resistance is an appealing and largely unexplored strategy in drug discovery. The objective of this study was to identify potential targets for “helper” drugs reversing cephem resistance in Escherichia coli strains producing β ...
Baker, K R, Guardabassi, L, Jana, B, Sigurðardóttir, H H   +3 more
core   +2 more sources